Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Ukraine: Russians abduct 50 Ukrainians from border village in Sumy - 2Takeda's AI-crafted psoriasis pill succeeds in late-stage studies
- 3'Peaky Blinders: The Immortal Man' teaser trailer reveals Cillian Murphy's Tommy Shelby back in action
- 4The Manual for Electric Vehicles that will be hot merchants in 2023
- 5Taylor Swift's 'The End of an Era' docuseries: Everything you need to know, plus how to watch for less
- Extravagance SUVs for Seniors: Solace, Innovation, and Security
- Flu cases spiking this holiday season, CDC data shows
- The Benefits of Effective money management for Your Youngsters' Future Monetary Prosperity
- What to expect from the planets in 2026 — key dates and sky events
- Our favorite Space.com stories of 2025
- Select Your Definitive Pizza Decision
- This Unique National Park In Canada Is Famous For Its Otherworldly Limestone Monoliths
- Instructions to Upgrade the Proficiency of Your Sunlight powered chargers
- German foreign minister heads to China to talk rare-earth exports
